December 19, 2006 Amorfix Receives Support from Canadian Government to Accelerate Development of Blood Test for Alzheimer's Disease
December 6, 2006 Amorfix CEO, George Adams, Accepts Congratulations at TSX Listing Ceremony, TSX Broadcast Centre
December 4, 2006 Canadian Company's Medical Technology Lauded by World Economic Forum as Having "Dramitc and Sustainable Impact on Society"
November 28, 2006 Amorfix Appoints Dr. Hans Black as a New Director
October 2, 2006 Amorfix Extends Epitope Protection Technology to Detect Sheep Scrapie Prions in Blood
September 18, 2006 Amorfix CEO Interviewed on CBC Radio One
September 12, 2006 Ontario Genomics Institute Completes Second Investment in Amorfix to Accelerate Development of a Blood Test for Alzheimer's Disease
September 5, 2006 Amorfix Achieves Technical Milestone in Development of a Blood Test for Alzheimer's Disease
August 3, 2006 Amorfix and Biogen Idec to Collaborate on Research for ALS Disease
June 21, 2006 Amorfix Announces Leading Sensitivity for Prion Detection in Spiked Human Blood Samples
June 16, 2006 Amorfix Announces William Lambert Joins Board
June 12, 2006 Amorfix Reports Annual Results for Fiscal 2006
May 25, 2006 Amorfix Issues Stock Options
April 4, 2006 Amorfix In-Licenses Second Novel Technology to Strenghten its ALS Therapeutic Program
March 24, 2006 Amorfix Completes Private Placement Financing
March 3, 2006 Amorfix Announces Private Placement Financing
February 2, 2006 "> Amorfix In-Licenses Novel Technology To Begin Therapeutic Program For Neurodegenerative Diseases
January 31, 2006 Amorfix and The Ontario Genomics Institute Announce Partnership To Accelerate Development Of A Blood Test for Alzheimer's Disease
January 26, 2006 Amorfix Reports Identification Of Epitopes On Bovine Prion Protein And Approval Of Laboratory For BSE Samples